Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody + FOLFIRINOX vs. PD-1 Antibody + SOX in Perioperative Gastric Cancer
NCT04908566Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Major Pathological Response. Started May 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04908566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908566.